Capricor Therapeutics Inc
Company Profile
Business description
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Contact
10865 Road to the Cure
Suite 150
San DiegoCA92121
USAT: +1 858 727-1755
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
231
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,352.80 | 40.50 | -0.43% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,714.89 | 203.79 | 0.80% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,227.55 | 371.12 | 0.56% |
| NZX 50 Index | 14,034.21 | 41.49 | 0.30% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,143.60 | 40.10 | -0.44% |
| SSE Composite Index | 3,918.95 | 29.51 | 0.76% |